

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION

International Bureau

09/480,251

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent classification⁶: C12N 15/82, 15/62, C07K 14/435, C12N 15/12, A01H 5/00, A01N 63/00	A1	(11) International publication number: WO 99/02717 (43) International publication date: 21 January 1999 (21.01.99)
(21) International application number: PCT/FR98/01462 (22) International filing date: 8 July 1998 (08.07.98) (30) Data relating to the priority: 97/09,115 11 July 1997 (11.07.97) FR 97/09,663 24 July 1997 (24.07.97) FR (71) Applicant (for all designated States except US): RHONE-POULENC AGRO [FR/FR]; 14-20, rue Pierre Baizet, F-69009 Lyon (FR). (72) Inventors; and (75) Inventors/Applicants (US only): DEROSE, Richard [US/FR]; 216, rue de Saint Cyr, F-69009 Lyon (FR). FREYSSINET, Georges [FR/FR]; 21, rue de Nervieux, F-69450 Saint Cyr au Mont d'Or (FR). HOFFMAN, Jules [FR/FR]; 5, rue Closener, F-67000 Strasbourg (FR). (74) Representative: TETAZ, Franck; Rhône-Poulenc Agro - D.P.I., Boîte postale 9163, F-69263 Lyon Cedex 09 (FR).		(81) Designated states: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO Patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With the International Search Report. Before expiry of the period provided for amending the claims, will be republished if such amendments are received.
<p style="text-align: center;">As printed</p> (54) Title: CHIMERIC GENE CODING FOR DROSOMICINE, VECTOR CONTAINING IT AND PRODUCTION OF TRANSGENIC PLANTS RESISTANT TO DISEASES (54) Titre: GENE CHIMERE CODANT POUR LA DROSOMICINE, VECTEUR LE CONTENANT ET OBTENTION DES PLANTES TRANSGENIQUES RESISTANTES AUX MALADIES (57) Abstract The invention concerns a chimeric gene containing a DNA sequence coding for drosomicine, a vector containing the chimeric gene, and a method for transforming plants and the resulting transformed plants. The drosomicine produced by the plants provides them with resistance to diseases, in particular of fungal origin. (57) Abrégé La présente invention a pour objet un gène chimère contenant une séquence d'ADN codant pour la drosomicine, un vecteur contenant le gène chimère, un procédé pour la transformation des plantes et les plantes transformées. La drosomicine produite par les plantes transformées leur confère une résistance aux maladies, en particulier d'origine fongique.		

CHIMERIC GENE ENCODING DROSOMYCIN, VECTOR CONTAINING IT
AND PRODUCTION OF DISEASE-RESISTANT TRANSGENIC PLANTS

The subject of the present invention is a DNA
5 sequence encoding drosomycin, a chimeric gene
containing it, a vector containing the chimeric gene
and a method of transforming plants and the disease-
resistant transformed plants.

There is nowadays an increasing need to make
10 plants resistant to diseases, in particular fungal
diseases, in order to reduce or even avoid the need to
resort to treatments with antifungal protection
products, so as to protect the environment. One way of
increasing this resistance to diseases consists in
15 transforming plants so that they produce substances
capable of providing their defence against these
diseases.

Various substances of natural origin, in
particular peptides, are known which have bactericidal
20 or fungicidal properties, in particular against fungi
responsible for plant diseases. However, the problem
consists in finding such substances which not only can
be produced by transformed plants, but can still
preserve their bactericidal or fungicidal properties
25 and confer them on the said plants. For the purposes of
the present invention, bactericide or fungicide is
understood to mean both the actual bactericidal or

fungicidal properties and the bacteriostatic or fungistatic properties.

Drosomycins are peptides produced by the larvae and adults of drosophila by induction following
5 septic injury or the injection of a low dose of bacteria. A peptide has already been described as having certain antifungal and antibacterial properties in vitro, in particular in French patent application 2,725,992, where the peptide is obtained by induction
10 in drosophila and purification. The gene encoding this same peptide has also been described by Fehlbaum et al. (1994). The possibility of integrating this gene into a plant to confer on it resistance to diseases of fungal or bacterial origin has, however, so far not been
15 described.

It has now been found that the genes for drosomycins could be inserted into plants to confer on them properties of resistance to fungal diseases and to diseases of bacterial origin, providing a particularly
20 advantageous solution to the problem set out above.

The subject of the invention is therefore firstly a chimeric gene comprising a nucleic acid fragment encoding a drosomycin as well as heterologous regulatory elements at positions 5' and 3' capable of
25 functioning in plants and a vector for the transformation of plants containing this chimeric gene. It also comprises a transformed plant cell containing at least one nucleic acid fragment encoding drosomycin

and a disease-resistant plant containing the said cell.
It finally relates to a method of transforming plants
to make them resistant to diseases, in which a gene
encoding drosomycin is inserted.

5 Drosomycin is understood to mean according to
the invention any peptide capable of being isolated
from the larvae and adults of drosophila by induction
following a septic injury or the injection of a low
dose of bacteria, these peptides comprising at least 44
10 amino acids and 8 cystein residues forming disulphide
bridges with each other.

Advantageously, drosomycin essentially
comprises the peptide sequence of formula (I) below:

Xaa-Cys-Xab-Cys-Xac-Cys-Xad-Cys-
15 Xae-Cys-Xaf-Cys-Xag-Cys-Xah-Cys (I)

in which

Xaa represents a peptide residue comprising at least 1
amino acid,

Xab represents a peptide residue of 8 amino acids,

20 Xac represents a peptide residue of 7 amino acids,

Xad represents a peptide residue of 3 amino acids,

Xae represents a peptide residue of 9 amino acids,

Xaf represents a peptide residue of 5 amino acids,

Xag represents a peptide residue of one amino acid,

25 and

Xah represents a peptide residue of 2 amino acids.

Advantageously, Xab and/or Xad and/or Xac
comprise at least one basic amino acid. More
advantageously, Xab comprises at least 2 basic amino
acids, preferably 2 and/or Xad and/or Xaf comprise at
5 least 1 basic amino acid, preferably 1. Basic amino
acid is understood to mean according to the invention
the amino acids chosen from lysine, arginine or
homoarginine.

Preferably,

- 10 Xaa represents the peptide sequence Xaa'-Asp- in which
Xaa' represents NH₂ or a peptide residue comprising
at least 1 amino acid, and/or
- Xab represents the peptide sequence -Leu-Xab'-Pro- in
which Xab' represents a peptide residue of 6 amino
15 acids, and/or
- Xac represents the peptide sequence -Ala-Xac'-Thr- in
which Xac' represents a peptide residue of 5 amino
acids, and/or
- Xad represents the peptide sequence -Arg-Xad'-Val, in
20 which Xad' represents a peptide residue of one
amino acid, and/or
- Xae represents the peptide sequence -Lys-Xae'-His- in
which Xae' represents a peptide residue of 7 amino
acids, and/or
- 25 Xaf represents the peptide sequence -Ser-Xaf'-Lys- in
which Xaf' represents a peptide residue of 3 amino
acids, and/or
- Xag represents Trp, and/or

Xah represents the peptide residue Glu-Gly.

Preferably,

Xab' represents the peptide sequence Ser-Gly-Arg-Tyr-
Lys-Gly, and/or

5 Xac' represents the peptide sequence Val-Trp-Asp-Asn-
Glu, and/or

Xad' represents Arg, and/or

Xae' represents the peptide sequence Glu-Glu-Gly-Arg-
Ser-Ser-Gly, and/or

10 Xaf' represents the peptide sequence Pro-Ser-Leu.

According to a more preferred embodiment of
the invention, drosomycin is the peptide sequence
represented by the sequence identifier No. 4 (SEQ ID
No. 4) and the homologous peptide sequences.

15 Homologous peptide sequences is understood to
mean any equivalent sequence comprising at least 65%
homology with the sequence represented by the sequence
identifier No. 4, it being understood that the 8
cystein residues and the number of amino acids
20 separating them remain identical, some amino acids
being replaced with different but equivalent amino
acids at sites which do not induce substantial
modification of the antifungal or antibacterial
activity of the said homologous sequence. Preferably,
25 the homologous sequences comprise at least 75%
homology, more preferably at least 85% homology, still
more preferably 90% homology.

The terminal NH₂ residue may exhibit a post-translational modification, for example an acetylation, in the same way that the C-terminal residue may exhibit a post-translational modification, for example an amidation.

Peptide sequence mainly comprising the peptide sequence of general formula (I) is understood to mean not only the sequences defined above, but also such sequences comprising at either of their ends, or both, peptide residues, in particular which are necessary for their expression and targeting in plant cells or in plants.

It is in particular "full-length" drosomycin represented by the sequence identifier No. 2 (SEQ ID No. 2).

It is in particular a "peptide-drosomycin" or "drosomycin-peptide", advantageously "peptide-drosomycin" fusion peptide, the cutting of which by the enzymatic systems of plant cells allows the liberation of the drosomycin defined above. The peptide fused with drosomycin may be a signal peptide or a transit peptide which makes it possible to control and orient the production of drosomycin in a specific manner in a part of the plant cell or of the plant, such as for example the cytoplasm, the cell membrane, or in the case of plants in a specific type of cell compartment or of tissues or in the extracellular matrix.

According to one embodiment, the transit peptide may be a chloroplast or mitochondrial addressing signal, which is then cleaved in the chloroplasts or mitochondria.

5 According to another embodiment of the invention, the signal peptide may be an N-terminal or "prepeptide" signal, optionally in combination with a signal responsible for retaining the protein in the endoplasmic reticulum, or a vacuolar addressing peptide
10 or "propeptide". The endoplasmic reticulum is the site where the "cellular machinery" carries out the operations of maturation of the protein produced, such as for example the cleavage of the signal peptide.

 The transit peptides may be either single, or
15 double, and in this case optionally separated by an intermediate sequence, that is to say comprising, in the direction of transcription, a sequence encoding a transit peptide for a plant gene encoding a plastid localization enzyme, a portion of sequence of the
20 N-terminal mature portion of a plant gene encoding a plastid localization enzyme, and then a sequence encoding a second transit peptide for a plant gene encoding a plastid localization enzyme, as described in Patent EP 0 508 909.

25 As transit peptide useful according to the invention, there may be mentioned in particular the signal peptide of the tobacco PR-1 α gene (WO 95/19443),

or alternatively the ubiquitin represented, fused with drosomycin by the sequence identifier No. 6.

The fusion peptide "ubiquitin-drosomycin" and its coding sequence are also included in the present invention, in particular described by the sequence identifier No. 5.

The present invention therefore relates to a chimeric gene comprising a sequence encoding drosomycin as well as heterologous regulatory elements at positions 5' and 3' capable of functioning in plants, the coding sequence comprising at least one DNA sequence encoding drosomycin as defined above.

The DNA sequence may be obtained according to standard methods of isolation and purification from drosophila, or alternatively by synthesis according to the usual techniques of successive hybridizations of synthetic oligonucleotides. These techniques are in particular described by Ausubel et al.

According to one embodiment of the invention, the DNA sequence encoding drosomycin comprises the DNA sequence described by bases 21 to 152 of the sequence identifier No. 3 (SEQ ID NO 3), a sequence homologous or complementary to the said sequence.

According to another embodiment of the invention, the DNA sequence encoding "full-length" drosomycin comprises the DNA sequence described by bases 101 to 310 of the sequence identifier No. 1 (SEQ

ID NO 1), a sequence homologous or complementary to the said sequence.

According to another embodiment of the invention, the DNA sequence encoding the "peptide-heliomycin" fusion peptide comprises the DNA sequence
5 described by bases 15 to 221 of the sequence identifier No. 5 (SEQ ID NO 5), a homologous sequence or a sequence complementary to the said sequences.

"Homologous" is understood to mean according
10 to the invention any DNA sequence having one or more sequence modifications compared with the nucleotide sequence described by the sequence identifiers No. 1, 3 or 5 and encoding drosomycin, "full-length" drosomycin or the "peptide-drosomycin" fusion peptide. These
15 modifications may be obtained according to the usual mutation techniques, or alternatively by choosing the synthetic oligonucleotides used in the preparation of the said sequence by hybridization. In the light of the multiple combinations of nucleic acids which can lead
20 to the expression of the same amino acid, the differences between the reference sequence described by the sequence identifiers No. 1, 3 or 5 and the corresponding homologue may be substantial, all the more so since they are small-sized DNA fragments which
25 can be made by chemical synthesis. Advantageously, the degree of homology will be at least 70% relative to the reference sequence, preferably at least 80%, more preferably at least 90%. These modifications are

generally neutral, that is to say that they do not affect the primary sequence of the resulting drosomycin or fusion peptide.

"Plant cell" is understood to mean according to the invention any cell derived from a plant and capable of constituting undifferentiated tissues such as calli, differentiated tissues such as embryos, plant portions, plants or seeds.

"Plant" is understood to mean according to the invention any differentiated multicellular organism capable of photosynthesis, in particular monocotyledonous or dicotyledonous plants, more particularly crop plants intended or not as animal feed or for human consumption, such as maize, wheat, colza, soya bean, rice, sugar cane, beet, tobacco, cotton and the like.

The regulatory elements necessary for the expression of the DNA sequence encoding drosomycin are well known to persons skilled in the art according to the plant. They comprise in particular promoter sequences, transcription activators, terminator sequences, including start and stop codons. The means and methods for identifying and selecting the regulatory elements are well known to persons skilled in the art. As promoter regulatory sequence in plants, there may be used any promoter sequence of a gene which is naturally expressed in plants, in particular a promoter of bacterial, viral or plant origin such as,

for example, that of a ribulose-biscarboxylase/
oxygenase (RuBisCO) small subunit gene or of a plant
virus gene such as, for example, that of the
cauliflower mosaic (CAMV 19S or 35S), or a promoter
5 inducible by pathogens such as tobacco PR-1a, it being
possible to use any known suitable promoter.
Preferably, a regulatory promoter sequence is used
which promotes the overexpression of the coding
sequence constitutively or inducibly upon attack by a
10 pathogen, such as for example that comprising at least
one histone promoter as described in application
EP 0 507 698.

According to the invention, it is also
possible to use, in combination with the regulatory
15 promoter sequence, other regulatory sequences, which
are situated between the promoter and the coding
sequence, such as transcription enhancers, such as for
example the translational enhancer of the tobacco
mosaic virus (TMV) described in application
20 WO 87/07644, or of the tobacco etch virus (TEV)
described by Carrington & Freed.

As regulatory terminator or polyadenylation
sequence, there may be used any corresponding sequence
of bacterial origin, such as for example the
25 *Agrobacterium tumefaciens* nos terminator, or
alternatively of plant origin, such as for example a
histone terminator as described in application
EP 0,633,317.

The present invention also relates to an integrating vector for the transformation of plants containing at least one chimeric gene as defined above.

The subject of the invention is also a method
5 of transforming plant cells by integration of at least one chimeric gene as defined above, which transformation may be obtained by any known appropriate means, widely described in the specialist literature and in particular the applications cited in the present
10 application.

One series of methods consists in bombarding cells or protoplasts with particles to which the DNA sequences are attached.

Another series of methods consists in using,
15 as means of transferring into the plant, a chimeric gene inserted into an *Agrobacterium tumefaciens* Ti plasmid or an *Agrobacterium rhizogenes* Ri plasmid.

Other methods may be used, such as microinjection or electroporation.

20 Persons skilled in the art will choose the appropriate method according to the nature of the plant, in particular its monocotyledonous or dicotyledonous character.

For the methods of transforming plant cells
25 and of regenerating plants, there may be mentioned the following patents and patent applications:

US 4,459,355, US 4,536,475, US 5,464,763, US 5,177,010,
US 5,187,073, EP 267,159, EP 604 662, EP 672 752,

US 4,945,050, US 5,036,006, US 5,100,792, US 5,371,014,
US 5,478,744, US 5,179,022, US 5,565,346, US 5,484,956,
US 5,508,468, US 5,538,877, US 5,554,798, US 5,489,520,
US 5,510,318, US 5,204,253, US 5,405,765, EP 442 174,
5 EP 486 233, EP 486 234, EP 539 563, EP 674 725,
WO 91/02071 and WO 95/06128.

The subject of the present invention is also
the plant cells, of monocotyledonous or dicotyledonous
plants, in particular of crops, which are transformed
10 and which contain in their genome an effective quantity
of a gene comprising a sequence encoding the drosomycin
defined above.

The subject of the present invention is also
the plants containing transformed cells, in particular
15 the plants regenerated from the transformed cells. The
regeneration is obtained by any appropriate method
which depends on the nature of the species, as for
example described in the above patents and
applications.

20 The subject of the present invention is also
the transformed plants derived from the cultivation
and/or the crossing of the above regenerated plants, as
well as the seeds of the transformed plants.

The plants thus transformed are resistant to
25 certain diseases, in particular to certain fungal
diseases. Because of this, the DNA sequence encoding
drosomycin may be integrated with the main objective of
producing plants resistant to the said diseases, the

drosomycin being effective against fungal diseases such as those caused by *Botrytis*, in particular *Botrytis cinerea* (mycelium or spores), *Cercospora*, in particular *Cercospora beticola*, *Septoria*, in particular *Septoria tritici*, or *Fusarium*, in particular *Fusarium culmorum* (mycelium or spores) or *Fusarium graminearum*.

The chimeric gene may also advantageously comprise at least one selectable marker, such as one or more genes for tolerance to herbicides.

10 The DNA sequence encoding drosomycin may also be integrated as a selectable marker during the transformation of plants with other sequences encoding other peptides or proteins of interest, such as for example genes for tolerance to herbicides.

15 Such genes for tolerance to herbicides are well known to persons skilled in the art and are in particular described in Patent Applications EP 115 673, WO 87/04181, EP 337 899, WO 96/38567 or WO 97/04103.

Of course, the cells and plants transformed
20 according to the invention may comprise, in addition to the sequence encoding drosomycin, other heterologous sequences encoding proteins of interest, such as other additional peptides capable of conferring on the plant resistance to other diseases of bacterial or fungal
25 origin, and/or other sequences encoding proteins for tolerance to herbicides and/or other sequences encoding proteins for resistance to insects, such as the *Bt* proteins in particular.

The other sequences may be integrated by means of the same vector comprising a chimeric gene, which comprises a first sequence encoding drosomycin and at least one other sequence encoding another peptide or protein of interest.

They may also be integrated by means of another vector comprising at least the said other sequence, according to the usual techniques defined above.

The plants according to the invention may also be obtained by the crossing of parents, one carrying the gene according to the invention encoding drosomycin, the other carrying a gene encoding at least one other peptide or protein of interest.

The present invention finally relates to a method of cultivating the transformed plants according to the invention, the method consisting in planting the seeds of the said transformed plants in an area of a field appropriate for the cultivation of the said plants, in applying to the said area of the said field an agrochemical composition, without substantially affecting the said seeds or the said transformed plants, and then in harvesting the cultivated plants when they reach the desired maturity and optionally in separating the seeds from the harvested plants.

Agrochemical composition is understood to mean according to the invention any agrochemical composition comprising at least one active product

having one of the following activities: herbicidal, fungicidal, bactericidal, virucidal or insecticidal activity.

According to a preferred embodiment of the method of cultivation according to the invention, the agrochemical composition comprises at least one active product having at least one fungicidal and/or bactericidal activity, more preferably exhibiting an activity complementary to that of the drosomycin produced by the transformed plants according to the invention.

Product exhibiting an activity complementary to that of drosomycin is understood to mean according to the invention a product exhibiting a complementary activity spectrum, that is to say a product which will be active against attacks by contaminants (fungi, bacteria or viruses) which are insensitive to drosomycin, or alternatively a product whose activity spectrum covers that of drosomycin, completely or in part, and whose dose for application will be substantially reduced because of the presence of the drosomycin produced by the transformed plant.

The examples below make it possible to illustrate the invention, the preparation of the chimeric gene, of the integrating vector, of the transformed plants and their resistance to various diseases of fungal origin. Figures 1 to 7 in the annex describe the schematic structures of some plasmids

prepared for the construction of the chimeric genes. In these figures, the different restriction sites are marked in *italics*.

5 **Example 1:** **Construction of the chimeric genes**

 All the techniques used below are standard laboratory techniques. The detailed protocols for these techniques are in particular described in Ausubel et
10 al.

pRPA-RD-180:

 A whole cDNA clone encoding drosomycin described by Fehlbaum et al. (SEQ ID NO. 1) is inserted into the plasmid pCR-1000 (INVITROGEN) as *EcoRI-HindIII*
15 fragment.

pRPA-RD-182: Creation of a region encoding so-called "full-length" drosomycin (corresponding to the pre-pro peptide) by removing the nontranscribed region in 5' and by eliminating the first ATG codon.

20 The plasmid pRPA-RD-180 is digested with the restriction enzymes *ScaI* and *EcoRI*, and the large DNA fragment is purified. A double-stranded synthetic oligonucleotide of the following sequence Oligo 1 is then linked to the purified DNA sequence derived from
25 pRPA-RD-180:

Oligo 1:

5' AATTCCCGAAGACGACATGCAGATCAAGT 3' ⁵⁰⁰
GGGCTTCTGCTGTACGTCTAGTTCA

pRPA-RD-183: Creation of a sequence encoding mature
5 drosomycin which does not comprise the nontranscribed
region in 3'.

The two complementary synthetic
oligonucleotides of sequences Oligo 2 and Oligo 3 below
are hybridized at 65°C for 5 minutes and then by a slow
10 reduction of the temperature to 30°C over 30'.

Oligo 2:

5' GAGAGATCCC CCGCGGTGGT GACTGCCTGT CCGGAAGATA
CAAGGGTCCC TGTGCCGTCT GGGACAACGA GACCTGTCGT
CGTGTGTGCA AGGAGGAGGG 3'

Oligo 3:

5' GCGCGCGGAT CCTTAGCATC CTTGCGACCA GCACTTCAGA
CTGGGGCTGC AGTGGCCACT GGAGCGTCCC TCCTCCTTGC
15 ACACACGACG 3'

After hybridization between Oligo 2 and
Oligo 3, the DNA remaining single-stranded serves as
template for the Klenow fragment of *E. coli* polymerase
20 I (under the standard conditions recommended by the
manufacturer (New England Biolabs)) for the creation of
the double-stranded oligonucleotide. This double-
stranded oligonucleotide is then digested with the
restriction enzymes *SacII* and *EcoRI* and cloned into the

plasmid pBS II SK(-) (Stratagene) digested with the same restriction enzymes. A clone is then obtained comprising the region encoding mature drosomycin situated between the *SacII* and *BamHI* restriction sites
5 (SEQ ID 3).

pRPA-RD-186: Removal of the nontranscribed 3' region from the region encoding full-length drosomycin of pRPA-RD-182.

The plasmid pRPA-RD-182 is digested with the
10 restriction enzymes *BspEI* and *KpnI*, and the large DNA fragment is purified. The plasmid pRPA-RD-183 is then digested with the restriction enzymes *BspEI* and *KpnI*, and the small DNA fragment is purified. These two purified fragments are then linked so as to obtain a
15 plasmid containing the region encoding the pre-pro peptide of drosomycin whose first ATG codon and the two noncoding regions in 5' and 3' have been eliminated (SEQ ID 5).

**pRPA-RD-187: Creation of a vector for expression in
20 plants comprising the sequence encoding the mature form of drosomycin.**

The plasmid pUGUS(118), derived from pUC-19, was obtained from Dr. Richard Vierstra of the University of Wisconsin (plasmid not described). This
25 plasmid, whose schematic structure is represented in Figure 1, contains the CaMV 35S promoter which directs the expression of an RNA containing the untranslated sequence in 5' of the alfalfa mosaic virus (AMV 5' UTR;

Brederode et al., 1980), the N-terminal region of the *Arabidopsis thaliana* ubiquitin gene ubql1 up to the ubiquitin hydrolase cleavage site (N-term ubql1; Callis et al., 1993) which is fused in the same reading frame
5 with the *E. coli* β -glucuronidase gene (GUS; Jefferson et al., 1987), followed by the polyadenylation site of the *Agrobacterium tumefaciens* nopaline synthase gene (NOS polyA; Bevan et al., 1983).

The plasmid pUGUS(118) is digested with the
10 restriction enzymes *SacII* and *BamHI* and the large DNA fragment is purified. The plasmid pRPA-RD-183 is digested with the restriction enzymes *SacII* and *BamHI* and the small DNA fragment containing the region encoding the mature form of drosomycin is then
15 purified. The two purified DNA fragments are linked together in a cassette for expression in plants which synthesize a ubiquitin-drosomycin fusion protein in the cytoplasm of plant cells. The schematic structure of this expression cassette is represented in Figure 2.
20 Under the action of ubiquitin hydrolase on this fusion protein, the mature drosomycin is liberated into the cytoplasm of the plant cells.

**pRPA-RD-188: Creation of a plant expression vector comprising the full length of the sequence encoding
25 drosomycin (pre-pro).**

The plasmid pRTL-2 GUS, derived from the plasmid pUC-19, was obtained from Dr. Jim Carrington (Texas A&M University, not described). This plasmid,

whose schematic structure is represented in Figure 3, contains the duplicated CaMV 35S promoter isolated from the cauliflower mosaic virus (CaMV 2×35S promoter; Odell et al., 1985) which directs the expression of an RNA containing tobacco etch virus 5' untranslated sequence (TEV 5' UTR; Carrington & Freed, 1990), the *E. coli* β -glucuronidase gene (GUS, Jefferson et al., 1987) followed by the CaMV 35S RNA polyadenylation site (CaMV polyA; Odell et al., 1985).

10 The plasmid pRTL-2 GUS is digested with the restriction enzymes *NcoI* and *BamHI* and the large DNA fragment is purified. The plasmid pRPA-RD-186 is digested with the restriction enzymes *BbsII* and *BamHI* and the small DNA fragment containing the region
15 encoding drosomycin pre-pro is purified. The two purified DNA fragments are then linked together in a cassette for expression in plants which synthesize a drosomycin pre-pro protein. The schematic structure of this expression cassette is represented in Figure 4.
20 "Pre-pro-drosomycin" represents the drosomycin coding region of pRPA-RD-186. The drosomycin is transported to the extracellular matrix of the plant by the action of a signal peptide (pre-pro).

pRPA-RD-195: Creation of a plasmid containing a
25 **modified multiple cloning site.**

 The plasmid pRPA-RD-195 is a plasmid derived from pUC-19 which contains a modified multiple cloning site. The complementary synthetic oligonucleotides

Oligo 4 and Oligo 5 below are hybridized and made double-stranded according to the procedure described for pRPA-RD-183.

5 Oligo 4: 5' AGGGCCCCCT AGGGTTTAAA CGGCCAGTCA GGCCGAATTC
GAGCTCGGTA CCCGGGGATC CTCTAGAGTC GACCTGCAGG
CATGC 3'

Oligo 5: 5' CCCTGAACCA GGCTCGAGGG CGCGCCTTAA TTAAAAGCTT
10 GCATGCCTGC AGGTCGACTC TAGAGG 3'

The double-stranded oligonucleotide obtained is then linked in pUC-19 which has been previously digested with the restriction enzymes *EcoRI* and *HindIII* and made blunt-ended using the Klenow fragment of
15 *E. coli* DNA polymerase I. A vector is obtained which contains multiple cloning sites to facilitate the introduction of the expression cassettes into an *Agrobacterium tumefaciens* vector plasmid. The schematic
20 structure of this multiple cloning site is represented in Figure 5.

pRPA-RD-190: Introduction of the drosomycin expression cassette from pRPA-RD-187 into pRPA-RD-195.

The plasmid pRPA-RD-187 is digested with the
25 restriction enzymes *KpnI* and *SalI*, and the DNA fragment containing the drosomycin expression cassette is purified. The purified fragment is then linked in

pRPA-RD-195 which has been previously digested with the same restriction enzymes.

pRPA-RD-191: Introduction of the drosomycin expression cassette from pRPA-RD-188 into pRPA-RD-195.

5 The plasmid pRPA-RD-188 is digested with the restriction enzyme *HindIII* and dephosphorylated with calf intestinal phosphatase. The DNA fragment containing the drosomycin expression cassette is purified. The purified fragment is then linked in
10 pRPA-RD-195 which has been previously digested with the restriction enzyme *HindIII*.

pRPA-RD-174: Plasmid derived from pRPA-BL-150A (EP 0,508,909) containing the bromoxynil tolerance gene of pRPA-BL-237 (EP 0,508,909).

15 The bromoxynil tolerance gene is isolated from pRPA-BL-237 by PCR gene amplification. The fragment obtained is blunt-ended and is cloned into the *EcoRI* site of pRPA-BL-150A which has been made blunt-ended by the action of Klenow polymerase under standard
20 conditions. An *Agrobacterium tumefaciens* vector is obtained which contains the bromoxynil tolerance gene near its right border, a kanamycin tolerance gene near its left border and the multiple cloning site of pUC-19 between these two genes.

25 The schematic structure of pRPA-RD-174 is represented in Figure 6. In this figure, "nos" represents the *Agrobacterium tumefaciens* nopaline synthase polyadenylation site (Bevan et al., 1983),

"NOS pro" represents the *Agrobacterium tumefaciens* nopaline synthase promoter (Bevan et al., 1983), "NPT II" represents the neomycin phosphotransferase gene of the *E. coli* Tn5 transposon (Rothstein et al., 5 1981), "35S pro" represents the 35S promoter isolated from the cauliflower mosaic virus (Odell et al., 1985), "BRX" represents the nitrilase gene isolated from *K. ozaenae* (Stalker et al., 1988), "RB" and "LB" represent respectively the right and left borders of 10 the sequence of an *Agrobacterium tumefaciens* Ti plasmid.

pRPA-RD-184: Addition of a new unique restriction site to pRPA-RD-174.

The complementary synthetic oligonucleotides 15 Oligo 6 and Oligo 7 below are hybridized and made double-stranded according to the procedure described for pRPA-RD-183.

Oligo 6: 5' CGGGCCAGTC AGGCCACACT TAATTAAGTT TAAACGCGGC
20 CCCGGCGCGC CTAGGTGTGT GCTCGAGGGC CCAACCTCAG
TACCTGGTTC AGG 3'

Oligo 7: 5' CCGGCCTGAA CCAGGTACTG AGGTTGGGCC CTCGAGCACA
CACCTAGGCG CGCCGGGGCC GCGTTTAAAC TTAATTAAGT
GTGGCCTGAC TGG 3'

25

The hybridized double-stranded oligonucleotide (95 base pairs) is purified after separation on an agarose gel (3% Nusieve, FMC). The

plasmid pRPA-RD-174 is digested with the restriction enzyme *XmaI*, and the large DNA fragment is purified. The two DNA fragments obtained are then linked.

A plasmid derived from pRPA-RD-174 is
5 obtained which comprises other restriction sites between the bromoxynil tolerance gene and the kanamycin selectable marker gene.

The schematic structure of the plasmid pRPA-RD-184 is represented in Figure 7, where the terms
10 "nos", "NPT II", "NOS pro", "35S pro", "BRX gene", "RB" and "LB" have the same meaning as in Figure 6.

pRPA-RD-192: Creation of an *Agrobacterium tumefaciens* vector containing the gene construct encoding drosomycin directed towards the cytosol of the cells.

15 The plasmid pRPA-RD-190 is digested with the restriction enzymes *ApaI* and *AscI*, and the DNA fragment containing the drosomycin expression cassette is purified. The purified DNA fragment containing the drosomycin expression cassette is linked into
20 pRPA-RD-184, after prior digestion with the same two enzymes. An *Agrobacterium tumefaciens* vector is thus obtained which contains the sequence encoding the drosomycin-ubiquitin fusion protein which leads to the expression of drosomycin in the cytosol of the plant
25 cells.

pRPA-RD-193: Creation of an *Agrobacterium tumefaciens* vector containing the gene construct encoding drosomycin directed towards the extracellular matrix.

The procedure described above is repeated with the plasmid pRPA-RD-191 and the restriction enzymes *PmeI* and *AscI*, replacing the plasmid pRPA-RD-190 and the restriction enzymes *ApaI* and *AscI*.

- 5 An *Agrobacterium tumefaciens* vector is thus obtained which contains the sequence encoding the drosomycin pre-pro protein which leads to the expression of drosomycin in the extracellular matrix of the plant.

Example 2: Herbicide tolerance of transformed

10 tobaccos.

2.1 - Transformation

- The vectors pRPA-RD-192 and pRPA-RD-193 are introduced into the *Agrobacterium tumefaciens* EHA101 strain (Hood et al., 1987) carrying the cosmid pTVK291
15 (Komari et al., 1986). The transformation technique is based on the procedure of Horsh et al. (1985).

2.2 - Regeneration

- The PBD6 tobacco (source SEITA France) is regenerated from foliar explants on a Murashige and
20 Skoog (MS) basal medium comprising 30 g/l of sucrose as well as 200 µg/ml of kanamycin. The foliar explants are removed from plants cultivated in a greenhouse or *in vitro* and transformed according to the foliar disc technique (Horsh et al., 1985) in three successive
25 stages: the first comprises the induction of shoots on a medium supplemented with 30 g/l of sucrose containing 0.05 mg/l of naphthyl acetic acid (NAA) and 2 mg/l of benzylaminopurine (BAP) for 15 days. The shoots formed

during this stage are then developed for 10 days by cultivating on an MS medium supplemented with 30 g/l of sucrose but not containing any hormone. Developed shoots are then removed and they are cultivated on an MS rooting medium containing half of the content of salts, vitamins and sugar and not containing any hormone. After about 15 days, the rooted shoots are transferred into the soil.

2.3 - Tolerance to bromoxynil

Twenty transformed plants were regenerated and transferred into a greenhouse for each construct pRPA-RD-192 and pRPA-RD-193. These plants were treated in a greenhouse at the 5-leaf stage with an aqueous Pardner suspension corresponding to 0.2 kg of bromoxynil active ingredient per hectare.

All the plants showing complete tolerance to bromoxynil are used in the following experiments to test the effects of the expression of drosomycin on the tolerance of the transformed plants to fungal attacks.

Example 3: Detection of drosomycin in transformed tobaccos

An immunoblot analysis (as described by Coligan et al.) is used to detect the drosomycin produced by the transformed tobaccos, using a rabbit antibody directed against synthetic drosomycin attached to a KLH carrier protein, with the synthetic drosomycin as antigen.

The leaf proteins are extracted, first by grinding the frozen tissues at -180°C , followed by the addition of an extraction buffer (8 M urea, 50 mM Tris-HCl pH 6.8, 2% SDS, 5% β -mercaptoethanol, 10% sucrose, 2 mM EDTA and 10 mM dithiothreitol). The total quantity of extractable proteins is then measured. 100 μg of extracted proteins are then loaded into SDS-PAGE gel (20% acrylamide) wells for an immunoblot analysis (according to Coligan et al.).

10 For the plants transformed with the plasmid pRPA-RD-193 (drosomycin pre-pro), up to 160 ng of drosomycin were found per 100 μg of total proteins extracted from the leaves.

For the plants transformed with the plasmid
15 pRPA-RD-192 (mature drosomycin), up to 50 ng of drosomycin were found per 100 μg of total proteins extracted from the leaves.

The drosomycin synthesized and isolated from the plants transformed with the plasmids pRPA-RD-192
20 and pRPA-RD-193 comigrates with the drosomycin isolated from drosophila. This result show that each of the drosomycins directed either towards the cytoplasm (pRPA-RD-192) or towards the extracellular matrix (pRPA-RD-193) leads to a mature drosomycin. In
25 addition, the gel system used in this analysis (20% acrylamide) would have made it possible to easily detect drosomycin which would not have been transformed since the two constructs (ubiquitin-drosomycin and

droso mycin pre-pro) are approximately 10 kD, against 5 kD for the mature droso mycin.

Example 4: Resistance of the transformed tobaccos to *Botrytis cinerea*

5 15/20 plants derived from the plants obtained in Example 2.3 are cultivated in a greenhouse in transplanting pots of side 7 cm under the following conditions:

- temperature: 16°C at night; 19°C during the day;
- 10 - photoperiod: 14 h of darkness; 10 h of daylight;
- hygrometry: 90-1400

Two leaves per plant are inoculated with 6 discs 6 mm in diameter per leaf, each disc consisting of a *Botrytis cinerea* suspension (100,000 spores/ml).
15 The development of the infection is observed 7 days after the inoculation by measuring the increase in the diameter of each disc.

For most of the plants transformed with the plasmid pRPA-RD-192 (mature protein in the cytoplasm) or with the plasmid pRPA-RD-193 (extracellular droso mycin), no increase in the diameters of the discs
20 or a very small increase, is observed, which indicates a high resistance to the infections caused by *Botritis cinerea*.

25 **Example 5: Resistance of transformed tobaccos to *Chalara elegans*.**

The preceding procedure is repeated with the following operating conditions:

- temperature: 18°C at night; 22°C during the day;
- photoperiod: 14 h of darkness; 10 h of daylight.

The inoculation is carried out 18 days after sowing by supplying to each pot 1 ml of a suspension of endoconidia containing 1,000,000 conidia/ml. The infection results are read 21 days after the inoculation by observing the roots of plantlets previously cleaned with water. The development of the disease is assessed on a marking scale from 0 to 11, 0 corresponding to an absence of infection. For the plants transformed with the plasmid pRPA-RD-192 (mature protein in the cytoplasm) and those transformed with the plasmid pRPA-RD-193 (extracellular drosomycin), the mean notation is 4, which corresponds to a high resistance to *Chalara elegans*.

The results obtained *in vivo* in Examples 4 and 5 show that the transformation with the chimeric gene according to the invention confers on the transformed plant new fungus resistance properties, an activity [lacuna] is linked to preservation of the antifungal properties of the drosomycin produced by the transformed plants according to the invention.

REFERENCES


- Ausubel, F.A. et al. (eds. Greene). Current Protocols in Molecular Biology. Publ. Wiley & Sons.
- Bevan, M. et al. (1983). Nuc. Acids Res. 11: 369-385.
- Brederode, F.T.M. et al. (1980). Nuc. Acids Res. 8: 2213-2223.

- Callis et al. (1993). *Plant Mol. Biol.* **21**: 895-906.
- Carrington and Freed (1990). *J. Virol.* **64**: 1590-1597.
- Coligan, J.E. et al. (ed. V.B. Chanda). *Current Protocols in Protein Science*. Publ. Wiley & Sons.
- 5 Fehlbauer et al. (1994). *J. Biol. Chem.* **269**: 331459-33163.
- Horsch et al. (1985). *Science* **227**: 1229-1231.
- Jefferson et al. (1987). *EMBO J.* **6**: 3901-3907.
- Komari et al. (1986). *J. Bacteriol.* **166**: 88-94.
- 10 Rothstein et al. (1981). *Cold Spring Harb. Symp. Quant. Biol.* **45**: 99-105.
- Stalker et al. (1988). *J. Biol. Chem.* **263**: 6310-6314.
- Odell, J.T. et al. (1985). *Nature* **313**: 810-812.

CLAIMS

1. Chimeric gene comprising a coding sequence as well as heterologous regulatory elements at positions 5' and 3' capable of functioning in a plant, characterized in that the coding sequence comprises at least one DNA sequence encoding drosomycin.

2. Chimeric gene according to Claim 1, characterized in that the drosomycin essentially comprises the peptide sequence of formula (I) below:



in which

Xaa represents a peptide residue comprising at least 1 amino acid,

15 Xab represents a peptide residue of 8 amino acids,

Xac represents a peptide residue of 7 amino acids,

Xad represents a peptide residue of 3 amino acids,

Xae represents a peptide residue of 9 amino acids,

Xaf represents a peptide residue of 5 amino acids,

20 Xag represents a peptide residue of one amino acid,

and

Xah represents a peptide residue of 2 amino acids.

3. Chimeric gene according to Claim 2, characterized in that Xab and/or Xad and/or Xac
25 comprise at least one basic amino acid.

4. Chimeric gene according to Claim 3, characterized in that Xab comprises at least 2 basic

amino acids, preferably 2 and/or Xad and/or Xaf
comprise at least 1 basic amino acid, preferably 1.

5. Chimeric gene according to either of
Claims 2 and 3, characterized in that

5 Xaa represents the peptide sequence Xaa'-Asp- in which
Xaa' represents NH₂ or a peptide residue comprising
at least 1 amino acid, and/or

Xab represents the peptide sequence -Leu-Xab'-Pro- in
which Xab' represents a peptide residue of 6 amino
10 acids, and/or

Xac represents the peptide sequence -Ala-Xac'-Thr- in
which Xac' represents a peptide residue of 5 amino
acids, and/or

Xad represents the peptide sequence -Arg-Xad'-Val, in
15 which Xad' represents a peptide residue of one
amino acid, and/or

Xae represents the peptide sequence -Lys-Xae'-His- in
which Xae' represents a peptide residue of 7 amino
acids, and/or

20 Xaf represents the peptide sequence -Ser-Xaf'-Lys- in
which Xaf' represents a peptide residue of 3 amino
acids, and/or

Xag represents Trp, and/or

Xah represents the peptide residue Glu-Gly.

25 6. Chimeric gene according to Claim 5,
characterized in that

Xab' represents the peptide sequence Ser-Gly-Arg-Tyr-Lys-Gly, and/or

Xac' represents the peptide sequence Val-Trp-Asp-Asn-Glu, and/or

5 Xad' represents Arg, and/or

Xae' represents the peptide sequence Glu-Glu-Gly-Arg-Ser-Ser-Gly, and/or

Xaf' represents the peptide sequence Pro-Ser-Leu.

7. Chimeric gene according to one of Claims
10 1 to 6, characterized in that the drosomycin is the peptide sequence represented by the sequence identifier No. 4 (SEQ ID No. 4) and the homologous peptide sequences.

8. Chimeric gene according to one of Claims
15 1 to 7, characterized in that the drosomycin is a "peptide-drosomycin" fusion peptide, the cutting of which by the enzymatic systems of plant cells allows the liberation of the drosomycin defined in Claims 1 to 7.

20 9. Chimeric gene according to Claim 8, characterized in that the "peptide-drosomycin" fusion peptide is represented by the sequence identifier No. 6 (SEQ ID No. 6).

10. "Peptide-drosomycin" fusion peptide,
25 characterized in that the drosomycin is defined according to Claims 1 to 7.

11. Fusion peptide according to Claim 10, characterized in that the peptide is to be a signal peptide or a transit peptide.

12. Fusion peptide according to Claim 11,
5 characterized in that the signal peptide is chosen from the signal peptide of the tobacco PR-1 α gene or ubiquitin.

13. Chimeric gene according to one of Claims 1 to 12, characterized in that it comprises, in
10 addition, at least one herbicide tolerance gene.

14. Chimeric gene according to one of Claims 1 to 14, characterized in that it comprises, in addition, at least one sequence encoding another peptide capable of conferring on the plant resistance
15 to other diseases of bacterial or fungal origin.

15. Chimeric gene according to one of Claims 1 to 14, characterized in that the regulatory elements comprise promoter sequences, transcription activators, transit peptides and/or terminator sequences.

16. Chimeric gene according to one of Claims 1 to 14, characterized in that the regulatory promoter sequence is chosen from promoter sequences of bacterial, viral or plant origin.

17. Chimeric gene according to Claim 16,
25 characterized in that the regulatory promoter sequence is chosen from the promoter of the gene for the ribulose-bisphosphate carboxylase/oxygenase (RuBisCO)

small subunit or that of the cauliflower mosaic (CAMV 19S or 35S).

18. Chimeric gene according to Claim 16, characterized in that the regulatory promoter sequence
5 comprises at least one promoter chosen from histone or actin promoters.

19. Vector for transforming plants, characterized in that it contains at least one chimeric gene according to one of Claims 1 to 18.

10 20. Transformed plant cell containing at least one DNA as defined in one of Claims 1 to 18.

21. Disease-resistant plant, characterized in that it comprises a transformed cell according to Claim 20.

15 22. Plant according to Claim 21, characterized in that it is obtained by regeneration from a transformed cell according to Claim 20.

20 23. Disease-resistant transformed plant, characterized in that it is derived from the cultivation and/or the crossing of plants according to either of Claims 21 and 22.

24. Seeds of transformed plants according to one of Claims 21 to 23.

25 25. Method of transforming plants to make them resistant to diseases, characterized in that a chimeric gene according to one of Claims 1 to 18 is inserted.

26. Method of transforming plants to make them resistant to fungal diseases, characterized in that a chimeric gene according to one of Claims 1 to 18 is inserted.

5 27. Method according to either of Claims 25 and 26, characterized in that the transfer is carried out with *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes*.

10 28. Method according to either of Claims 25 and 26, characterized in that the transfer is carried out by supplying by bombardment with the aid of particles charged with DNA.

15 29. Method according to one of Claims 25 to 28, characterized in that at least one herbicide tolerance gene is also inserted.

20 30. Method according to one of Claims 25 to 29, characterized in that at least one sequence encoding another peptide capable of conferring on the plant resistance to other diseases of bacterial or fungal origin is also inserted.

31. Method of cultivating the transformed plants according to one of Claims 21 to 24, characterized in that it consists in planting the seeds of the said transformed plants in an area of a field appropriate for the cultivation of the said plants, in applying to the said area of the said field an agrochemical composition, without substantially

25

affecting the said seeds or the said transformed plants, and then in harvesting the cultivated plants when they reach the desired maturity and optionally in separating the seeds from the harvested plants.

5 32. Method of cultivation according to Claim 31, characterized in that the agrochemical composition comprises at least one active product having at least one fungicidal and/or bactericidal activity.

10 33. Method of cultivation according to Claim 24, characterized in that the active product exhibits activity complementary to that of drosomycin.

1/2




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: RHONE-POULENC AGROCHIMIE

5 (B) STREET: 14/20 Rue Pierre BAIZET

(C) CITY: Lyon

(E) COUNTRY: France

(F) POSTAL CODE: 69009

10 (ii) TITLE OF INVENTION: Chimeric gene encoding
drosomycin, vector containing it for the
transformation of plant cells and disease-
resistant transformed plants obtained

(iii) NUMBER OF SEQUENCES: 14

(iv) COMPUTER READABLE FORM:

15 (A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version
#1.30 (EPO)

20 (2) INFORMATION FOR SEQ ID NO: 1 :

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 488 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

25 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

REPLACEMENT SHEET (RULE 26)

(A) ORGANISM: *Drosophila melanogaster*

(vii) IMMEDIATE SOURCE:

(B) CLONE: pRPA-RD-180

(ix) ADDITIONAL FEATURE:

5

(A) NAME/KEY: CDS

(B) LOCATION: 101..310

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 :

GAATTCGAGC TGGGTACCCC TCGAGACCAT GGTGACCCC ACCGCTCCCG ATAATCTTT	60
CAGAAATCAT TTACCAAGCT CCGTGAGAAC CTTTTCATAT ATG ATG CAG ATC AAG	115
Met Met Gln Ile Lys	5
1	
TAC TTG TTC GCC CTC TTC GCT GTC CTG ATG CTG GTG GTG CTG GGA GCC	163
Tyr Leu Phe Ala Leu Phe Ala Val Leu Met Leu Val Val Leu Gly Ala	20
10 15	
AAC GAG GCC GAT GCC GAC TGC CTG TCC GGA AGA TAC AAG GGT CCC TGT	211
Asn Glu Ala Asp Ala Asp Cys Leu Ser Gly Arg Tyr Lys Gly Pro Cys	35
25 30	
GCC GTC TGG GAC AAC GAG ACC TGT CGT CGT GTG TGC AAG GAG GAG GGA	259
Ala Val Trp Asp Asn Glu Thr Cys Arg Arg Val Cys Lys Glu Glu Gly	50
40 45	
CGC TCC AGT GGC CAC TGC AGC CCC AGT CTG AAG TGC TGG TGC GAA GGA	307
Arg Ser Ser Gly His Cys Ser Pro Ser Leu Lys Cys Trp Cys Glu Gly	65
55 60	
TGC TAAATCCATG AGCAATTAGC ATGAACGTTT TGAAGACGC GTTTAGCTCT	360
Cys	70
70	
CCACTACTTA CGACATATTC TATGCTGCAA TATTGAAAT CTAATAACA AAACATATG	420
ACATTAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAGGG CCGCCCGCAC CTGCAGGCAT	480
GCAAGCTT	488

10

(2) INFORMATION FOR SEQ ID NO: 2 :

(i) SEQUENCE CHARACTERISTICS:

REPLACEMENT SHEET (RULE 26)

(A) LENGTH: 70 amino acids

(B) TYPE: amino acids

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2 :

```

Met Met Gln Ile Lys Tyr Leu Phe Ala Leu Phe Ala Val Leu Met Leu
 1           5           10           15
Val Val Leu Gly Ala Asn Glu Ala Asp Ala Asp Cys Leu Ser Gly Arg
          20           25           30
Tyr Lys Gly Pro Cys Ala Val Trp Asp Asn Glu Thr Cys Arg Arg Val
 35           40           45
Cys Lys Glu Glu Gly Arg Ser Ser Gly His Cys Ser Pro Ser Leu Lys
 50           55           60
Cys Trp Cys Glu Gly Cys
 65           70

```

(2) INFORMATION FOR SEQ ID NO: 3 :

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 167 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Synthetic

(vii) IMMEDIATE SOURCE:

(B) CLONE: pRPA-RD-183

20 (ix) FEATURE:

REPLACEMENT SHEET (RULE 26)

(A) NAME/KEY: CDS

(B) LOCATION: 21..152

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3 :

GAGAGATCCC	CCCCGGTGGT	GAC	TGC	CTG	TCC	GGA	AGA	TAC	AAG	GGT	CCC	50				
	Asp	Cys	Leu	Ser	Gly	Arg	Tyr	Lys	Gly	Pro						
	1				5					10						
TGT	GCC	GTC	TGG	GAC	AAC	GAG	ACC	TGT	CCT	CCT	GTC	TGC	AAG	GAG	GAG	98
Cys	Ala	Val	Trp	Asp	Asn	Glu	Thr	Cys	Arg	Arg	Val	Cys	Lys	Glu	Glu	
				15				20						25		
GGA	CGC	TCC	AGT	GGC	CAC	TGC	AGC	CCC	AGT	CTG	AAG	TGC	TGG	TGC	GAA	146
Gly	Arg	Ser	Ser	Gly	His	Cys	Ser	Pro	Ser	Leu	Lys	Cys	Trp	Cys	Glu	
			30					35					40			
GGA	TGC	TAAGGATCCG	CGCGC													167
Gly	Cys															

5

(2) INFORMATION FOR SEQ ID NO: 4 :

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 44 amino acids

10 (B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4 :

Asp	Cys	Leu	Ser	Gly	Arg	Tyr	Lys	Gly	Pro	Cys	Ala	Val	Trp	Asp	Asn
1				5				10						15	
Glu	Thr	Cys	Arg	Arg	Val	Cys	Lys	Glu	Glu	Gly	Arg	Ser	Ser	Gly	His
			20					25					30		
Cys	Ser	Pro	Ser	Leu	Lys	Cys	Trp	Cys	Glu	Gly	Cys				
		35					40								

15

(2) INFORMATION FOR SEQ ID NO: 5 :

(i) SEQUENCE CHARACTERISTICS:

REPLACEMENT SHEET (RULE 26)

- (A) LENGTH: 236 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Synthetic

(vii) IMMEDIATE SOURCE:

(B) CLONE: pRPA-RD-186

10 (ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 15..221

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5 :

GAATTGAAGA CGCC ATG CAG ATC AAG TAC TTG TTC GCC CTC TTC GCT GTC	50
Met Gln Ile Lys Tyr Leu Phe Ala Leu Phe Ala Val	
1 5 10	
CTG ATG CTG GTG GTG CTG GGA GCC AAC GAG GCC GAT GCC GAC TGC CTG	98
Leu Met Leu Val Val Leu Gly Ala Asn Glu Ala Asp Ala Asp Cys Leu	
15 20 25	
TCC GGA AGA TAC AAG GGT CCC TGT GCC GTC TGG GAC AAC GAG ACC TGT	146
Ser Gly Arg Tyr Lys Gly Pro Cys Ala Val Trp Asp Asn Glu Thr Cys	
30 35 40	
CGT CGT GTG TGC AAG GAG GAG GGA CCC TCC AGT GGC CAC TGC AGC CCC	194
Arg Arg Val Cys Lys Glu Glu Gly Arg Ser Ser Gly His Cys Ser Pro	
45 50 55 60	
AGT CTG AAG TGC TGG TGC GAA GGA TGC TAAGGATCCG CGCGC	236
Ser Leu Lys Cys Trp Cys Glu Gly Cys	
65	

15

(2) INFORMATION FOR SEQ ID NO: 6 :

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 69 amino acids

REPLACEMENT SHEET (RULE 26)

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6 :

```

Met Gln Ile Lys Tyr Leu Phe Ala Leu Phe Ala Val Leu Met Leu Val
 1           5           10           15
Val Leu Gly Ala Asn Glu Ala Asp Ala Asp Cys Leu Ser Gly Arg Tyr
          20           25           30
Lys Gly Pro Cys Ala Val Trp Asp Asn Glu Thr Cys Arg Arg Val Cys
          35           40           45
Lys Glu Glu Gly Arg Ser Ser Gly His Cys Ser Pro Ser Leu Lys Cys
          50           55           60
Trp Cys Glu Gly Cys
          65

```

5

(2) INFORMATION FOR SEQ ID NO: 7 :

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA Synthetic Oligonucleotide 1

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7 :

AATTCCCGAA GACGACATGC AGATCAAGT

29

(2) INFORMATION FOR SEQ ID NO: 8 :

20 (i) SEQUENCE CHARACTERISTICS:

REPLACEMENT SHEET (RULE 26)

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: DNA Synthetic Oligonucleotide 1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8 :

GGGCTTCTGC TGTACGTCTA GTTCA

25

10 (2) INFORMATION FOR SEQ ID NO: 9 :

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 100 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: DNA Synthetic Oligonucleotide 2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9 :

GAGAGATCCC CCGCGGTGGT GACTGCCTGT CCGGAAGATA CAAGGGTCCC TGTGCCGTCT

60

GCGACAACGA GACCTGTCTT CTGTGTGCA AGGAGGAGGG

100

20

(2) INFORMATION FOR SEQ ID NO: 10 :

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 100 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

25

REPLACEMENT SHEET (RULE 26)

(ii) MOLECULE TYPE: DNA Synthetic Oligonucleotide 3

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10 :

```

GGGCGCGGAT CCTTAGCATC CTTCGCACCA GCACTTCAGA CTGGGGCTGC AGTGCCACT      60
GGAGGTCCC TCCTCCTTGC ACACAGGAGG                                     100

```

5

(2) INFORMATION FOR SEQ ID NO: 11 :

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 85 base pairs

(B) TYPE: nucleic acid

10 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Synthetic Oligonucleotide 4

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11 :

```

AGGGCCCCCT AGGGTTTAA CCGCCAGTCA GCGCGAATC GAGCTCGGTA CCGGGGATC      60
CTCTAGAGTC GACCTGCAGG CATGC                                           85

```

(2) INFORMATION FOR SEQ ID NO: 12 :

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 66 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: DNA Synthetic Oligonucleotide 5

REPLACEMENT SHEET (RULE 26)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12 :

CCCTGAACCA GGCTCGAGGG CCGCCTTAA TTAAAGCTT GCATGCTGC AGGTGACTC 60
TAGAGG 66

5 (2) INFORMATION FOR SEQ ID NO: 13 :

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 93 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA Synthetic Oligonucleotide 6

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13 :

CGGGCCAGTC AGGCCACACT TAATTAAGTT TAAACGGGC CCGGGCGGC CTAGGTGTGT 60
GCTCGAGGGC CCAACTCAG TACCTGTTTC AGG 93

15

(2) INFORMATION FOR SEQ ID NO: 14 :

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 93 base pairs

(B) TYPE: nucleic acid

20 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA Synthetic Oligonucleotide 7

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14 :

CCGGCCTGAA CCAAGTACTG AGGTTGGGCC CTCGAGACA CACCTAGGCG CCGCGGGGCC 60
CGGTTTAAAC TTAATTAAGT GTGCGCTGAC TGG 93

REPLACEMENT SHEET (RULE 26)

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 6	C12N15/82	C12N15/62 C07K14/435 C12N15/12 A01H5/00
A01N63/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC 6 C12N C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	P. FELHBAUM ET AL.: "Insect immunity. Septic injury of <i>Drosophila</i> induces the synthesis of a potent antifungal peptide with sequence homology to plant antifungal peptides" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, 1994, pages 33159-33163, XP002061373 BETHESDA, MD, US cited in the application see the whole document	1-11, 13, 15-24, 27, 29, 31-33
Y	EP 0 507 698 A (RHONE-POULENC AGROCHIMIE) 7 October 1992 cited in the application see example 1	1-11, 13, 15-24, 27, 29, 31-33
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "S" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
26 November 1998		03/12/1998
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 MV Rijswijk Tel (+31-70) 340-2040, Tx. 31 651 epo nl Fax: (+31-70) 340-3016		Authorized officer Mateo Rosell, A.M.

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	FR 2 725 992 A (RHONE POULENC AGROCHIMIE) 26 April 1996 cited in the application see the whole document ---	1-10
A	WO 96 03522 A (DEMETER BIOTECH LTD) 8 February 1996 see page 6, line 30 - page 7, line 13 ---	1, 12, 15, 19-23, 25, 26
A	EP 0 508 909 A (RHONE POULENC AGROCHIMIE) 14 October 1992 cited in the application see the whole document ---	1, 11, 13, 15-17, 19-24, 27, 29
A	WO 91 19738 A (HOECHST AG) 26 December 1991 see the whole document ---	1, 19-26
A	WO 93 19188 A (MAX PLANCK GESELLSCHAFT) 30 September 1993 see page 5, line 5-37 see page 7, line 7-15 ---	1, 15, 16, 19-26
A	WO 95 14098 A (BIOTECHNOLOGY RES & DEV) 26 May 1995 see abstract ---	1, 9, 10, 19
A	H. LEE ET AL.: "Structure and expression of ubiquitin genes of Drosophila melanogaster" MOLECULAR AND CELLULAR BIOLOGY, vol. 8, no. 11, 1988, pages 4727-4735, XP000644354 WASHINGTON, DC, US see the whole document -----	12

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0507698	A	07-10-1992	FR 2673642 A	11-09-1992
			AU 652417 B	25-08-1994
			AU 1144392 A	10-09-1992
			CA 2061835 A	06-09-1992
			JP 5076369 A	30-03-1993
			MX 9200916 A	01-09-1992
			US 5491288 A	13-02-1996
			US 5792930 A	11-08-1998
FR 2725992	A	26-04-1996	NONE	
WO 9603522	A	08-02-1996	AU 3199595 A	22-02-1996
			AU 3199695 A	22-02-1996
			CA 2195625 A	08-02-1996
			EP 0781347 A	02-07-1997
			JP 10507069 T	14-07-1998
			WO 9603519 A	08-02-1996
EP 0508909	A	14-10-1992	FR 2673643 A	11-09-1992
			AT 169338 T	15-08-1998
			AU 652610 B	01-09-1994
			AU 1144292 A	10-09-1992
			CA 2061636 A	06-09-1992
			DE 69226466 D	10-09-1998
			EP 0879891 A	25-11-1998
			ES 2118802 T	01-10-1998
			IL 101115 A	10-01-1997
			JP 5095789 A	20-04-1993
			MX 9200915 A	01-09-1992
			US 5510471 A	23-04-1996
			US 5633448 A	27-05-1997
WO 9119738	A	26-12-1991	AT 118788 T	15-03-1995
			DE 59104720 D	30-03-1995
			DK 535060 T	17-07-1995
			EP 0535060 A	07-04-1993
			ES 2071319 T	16-06-1995
			GR 3015741 T	31-07-1995
			JP 6500074 T	06-01-1994
			US 5589624 A	31-12-1996
			US 5824874 A	20-10-1998
			US 5421839 A	06-06-1995
WO 9319188	A	30-09-1993	AU 676471 B	13-03-1997
			AU 3751393 A	21-10-1993
			CA 2132323 A	30-09-1993
			EP 0631629 A	04-01-1995
			JP 7506485 T	20-07-1995
			US 5723760 A	03-03-1998
			US 5750874 A	12-05-1998
WO 9514098	A	26-05-1995	AU 687961 B	05-03-1998
			AU 1288595 A	06-06-1995
			BR 9408093 A	12-08-1997
			CN 1136825 A	27-11-1996
			EP 0729514 A	04-09-1996
			JP 9505205 T	27-05-1997

PCT/FR 98/01462

A. CLASSEMENT DE L'OBJET DE LA DEMANDE
 CIB 6 C12N15/82 C12N15/62 C07K14/435 C12N15/12 A01H5/00
 A01N63/00

Selon la classification internationale des brevets (CIB) ou à la fois selon la classification nationale et la CIB

B. DOMAINES SUR LESQUELS LA RECHERCHE A PORTE

Documentation minimale consultée (système de classification suivi des symboles de classement)

CIB 6 C12N C07K

Documentation consultée autre que la documentation minimale dans la mesure où ces documents relèvent des domaines sur lesquels a porté la recherche

Base de données électronique consultée au cours de la recherche internationale (nom de la base de données, et si cela est réalisable, termes de recherche utilisés)

C. DOCUMENTS CONSIDERES COMME PERTINENTS

Catégorie Identification des documents cités, avec, le cas échéant, l'indication des passages pertinents

no des revendications visées

Y	P. FELHBAUM ET AL.,: "Insect immunity. Septic injury of Drosophila induces the synthesis of a potent antifungal peptide with sequence homology to plant antifungal peptides" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, 1994, pages 33159-33163, XP002061373 BETHESDA, MD, US cité dans la demande voir le document en entier ---	1-11,13, 15-24, 27,29, 31-33
Y	EP 0 507 698 A (RHONE POULENC AGROCHIMIE) 7 octobre 1992 cité dans la demande voir exemple 1 --- -/--	1-11,13, 15-24, 27,29, 31-33

☒ Voir la suite du cadre C pour la fin de la liste des documents

☒ Les documents de familles de brevets sont indiqués en annexe

* Catégories spéciales de documents cités:

- "A" document définissant l'état général de la technique, non considéré comme particulièrement pertinent
- "E" document antérieur, mais publié à la date de dépôt international ou après cette date
- "L" document pouvant jeter un doute sur une revendication de priorité ou cité pour déterminer la date de publication d'une autre citation ou pour une raison spéciale (elle qu'indiquée)
- "O" document se référant à une divulgation orale, à un usage, à une exposition ou tous autres moyens
- "P" document publié avant la date de dépôt international, mais postérieurement à la date de priorité revendiquée

"T" document ultérieur publié après la date de dépôt international ou la date de priorité et n'appartenant pas à l'état de la technique pertinent, mais cité pour comprendre le principe ou la théorie constituant la base de l'invention

"X" document particulièrement pertinent; l'invention revendiquée ne peut être considérée comme nouvelle ou comme impliquant une activité inventive par rapport au document considéré isolément

"Y" document particulièrement pertinent; l'invention revendiquée ne peut être considérée comme impliquant une activité inventive lorsque le document est associé à un ou plusieurs autres documents de même nature, cette combinaison étant évidente pour une personne du métier

"Z" document qui fait partie de la même famille de brevets

Date à laquelle la recherche internationale a été effectivement achevée

26 novembre 1998

Date d'expédition du présent rapport de recherche internationale

03/12/1998

Nom et adresse postale de l'administration chargée de la recherche internationale

Office Européen des Brevets, P. B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tél. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Fonctionnaire autorisé

Mateo Rosell, A.M.

C.(suite) DOCUMENTS CONSIDERES COMME PERTINENTS		
Catégorie	Identification des documents cités, avec le cas échéant, l'indication des passages pertinents	no des revendications visées
X	FR 2 725 992 A (RHONE POULENC AGROCHIMIE) 26 avril 1996 cité dans la demande voir le document en entier ---	1-10
A	WO 96 03522 A (DEMETER BIOTECH LTD) 8 février 1996 voir page 6, ligne 30 - page 7, ligne 13 ---	1, 12, 15, 19-23, 25, 26
A	EP 0 508 909 A (RHONE POULENC AGROCHIMIE) 14 octobre 1992 cité dans la demande voir le document en entier ---	1, 11, 13, 15-17, 19-24, 27, 29
A	WO 91 19738 A (HOECHST AG) 26 décembre 1991 voir le document en entier ---	1, 19-26
A	WO 93 19188 A (MAX PLANCK GESELLSCHAFT) 30 septembre 1993 voir page 5, ligne 5-37 voir page 7, ligne 7-15 ---	1, 15, 16, 19-26
A	WO 95 14098 A (BIOTECHNOLOGY RES & DEV) 26 mai 1995 voir abrégé ---	1, 9, 10, 19
A	H. LEE ET AL.: "Structure and expression of ubiquitin genes of Drosophila melanogaster" MOLECULAR AND CELLULAR BIOLOGY, vol. 8, no. 11, 1988, pages 4727-4735, XP000644354 WASHINGTON, DC, US voir le document en entier -----	12

Document brevet cité au rapport de recherche		Date de publication	Membre(s) de la famille de brevet(s)	Date de publication
EP 0507698	A	07-10-1992	FR 2673642 A	11-09-1992
			AU 652417 B	25-08-1994
			AU 1144392 A	10-09-1992
			CA 2061835 A	06-09-1992
			JP 5076369 A	30-03-1993
			MX 9200916 A	01-09-1992
			US 5491288 A	13-02-1996
			US 5792930 A	11-08-1998
FR 2725992	A	26-04-1996	AUCUN	
WO 9603522	A	08-02-1996	AU 3199595 A	22-02-1996
			AU 3199695 A	22-02-1996
			CA 2195625 A	08-02-1996
			EP 0781347 A	02-07-1997
			JP 10507069 T	14-07-1998
			WO 9603519 A	08-02-1996
EP 0508909	A	14-10-1992	FR 2673643 A	11-09-1992
			AT 169338 T	15-08-1998
			AU 652610 B	01-09-1994
			AU 1144292 A	10-09-1992
			CA 2061636 A	06-09-1992
			DE 69226466 D	10-09-1998
			EP 0879891 A	25-11-1998
			ES 2118802 T	01-10-1998
			IL 101115 A	10-01-1997
			JP 5095789 A	20-04-1993
			MX 9200915 A	01-09-1992
			US 5510471 A	23-04-1996
			US 5633448 A	27-05-1997
WO 9119738	A	26-12-1991	AT 118788 T	15-03-1995
			DE 59104720 D	30-03-1995
			DK 535060 T	17-07-1995
			EP 0535060 A	07-04-1993
			ES 2071319 T	16-06-1995
			GR 3015741 T	31-07-1995
			JP 6500074 T	06-01-1994
			US 5589624 A	31-12-1996
			US 5824874 A	20-10-1998
			US 5421839 A	06-06-1995
WO 9319188	A	30-09-1993	AU 676471 B	13-03-1997
			AU 3751393 A	21-10-1993
			CA 2132323 A	30-09-1993
			EP 0631629 A	04-01-1995
			JP 7506485 T	20-07-1995
			US 5723760 A	03-03-1998
WO 9514098	A	26-05-1995	US 5750874 A	12-05-1998
			AU 687961 B	05-03-1998
			AU 1288595 A	06-06-1995
			BR 9408093 A	12-08-1997
			CN 1136825 A	27-11-1996
			EP 0729514 A	04-09-1996
			JP 9505205 T	27-05-1997